Executive Summary
Clinical trials are moving beyond the traditional model in which participants repeatedly visit research sites for assessments, monitoring, and study procedures. Site-less and decentralized approaches use digital tools, local healthcare providers, home-based services, and remote data collection to bring suitable activities closer to participants.
The shift reflects pressure to reduce participant burden, improve recruitment and retention, reach broader populations, and manage trials efficiently. Telehealth, wearables, electronic consent, direct-to-patient logistics, and integrated platforms can support remote participation, but site-less models are not appropriate for every protocol. Studies requiring specialized procedures or close observation may still need in-person care. The opportunity is to determine which activities can be remote, which require local clinical support, and which must remain on site—without compromising safety, data quality, or scientific rigor.
Key Themes
- Reducing travel and participation burden
- Expanding remote care and digital data collection
- Improving recruitment, retention, and geographic reach
- Connecting trial technology, logistics, and data workflows
- Balancing efficiency with safety and evidence quality
1. Growing Demand for Patient-Centric Research
Frequent site visits create barriers such as travel costs, time away from work, childcare needs, and mobility limitations. These burdens can contribute to missed visits or withdrawal, especially in long-running studies.
Site-less models can move suitable activities into participants’ homes or local communities. The goal is to fit participation around real-life circumstances while preserving consistent procedures and clinical oversight. Sponsors must consider whether remote participation suits the target population and whether participants have the technology and support they need.
2. Expansion of Telehealth and Virtual Assessments
Telehealth enables selected consultations, symptom reviews, follow-ups, and safety checks to take place remotely. Video visits and secure messaging can reduce travel while keeping teams connected with participants between in-person assessments.
Remote care is not suitable for every examination or urgent evaluation. Protocols need clear escalation rules, documentation standards, and referral pathways to local healthcare professionals. Telehealth works best when integrated into clinical workflows rather than treated as a separate communication channel.
3. Wearables and Remote Patient Monitoring
Wearables and connected devices can collect measures such as activity, heart rate, sleep, and selected physiological signals between visits. These data may show how participants function in daily life, beyond snapshots taken during clinic appointments.
Usefulness depends on device validity, adherence, connectivity, and data completeness. Sponsors must define how readings are reviewed and what actions follow alerts. More data do not automatically produce better evidence: collection should support meaningful endpoints and a prespecified analysis plan.
4. Direct-to-Patient Investigational Product Delivery
Home delivery can eliminate trips made only to collect study medication or supplies when the product and protocol permit it. Logistics providers may manage packaging, shipment, temperature monitoring, delivery confirmation, and returns.
Sponsors must protect product integrity, confirm receipt, maintain accountability records, and explain storage and administration. Products requiring supervised administration, specialized handling, or close observation may not suit home delivery. Logistics must reflect product risk and protocol requirements, not convenience alone. Clear contingency plans are needed for delayed shipments, temperature excursions, missed deliveries, and product returns.
5. Electronic Informed Consent and Digital Documentation
Electronic informed consent lets participants review study information and complete consent remotely, with opportunities to ask questions. Digital records can improve tracking, version control, and visibility into outstanding tasks.
Consent is more than an electronic signature. Participants must understand the study, risks, alternatives, and rights and make a voluntary decision. Sponsors should provide accessible materials, language options, identity verification, human support, and records that meet applicable requirements for privacy, electronic signatures, and data integrity. Participants should be able to pause, ask questions, and obtain a copy of the completed consent record.
6. Integrated Decentralized Trial Platforms
Site-less trials combine eConsent, telehealth, electronic patient-reported outcomes, device data, scheduling, logistics, and safety workflows. Integrated platforms can reduce duplicate entry and give teams a consolidated view of activities.
Benefits depend on reliable data exchange. Sponsors should assess interoperability, access controls, audit trails, vendor oversight, data ownership, and continuity plans. A fragmented technology stack can replace travel with digital friction, so platform choices should follow operational needs rather than feature count.
7. Digital Biomarkers and Remote Data Collection
Digital biomarkers use device or software data to measure physiology, behavior, or disease-related changes. Depending on the condition and validation evidence, they may track mobility, sleep, motor function, activity, or symptoms in everyday settings.
Sponsors must establish that measures are reliable and fit for purpose. Algorithms, device versions, collection conditions, and missing data can affect results. Digital endpoints should answer a clinical question, with validation and analysis specified in advance—not be selected simply because a sensor can collect them.
8. Broader Geographic Reach and More Inclusive Recruitment
Remote participation can make trials more feasible for people living far from research centers or facing transportation barriers. It may help sponsors reach populations underrepresented in conventional studies.
Digital delivery does not guarantee inclusion. Broadband, device access, language, disability access, digital literacy, and trust can create barriers. Sponsors may need to supply devices, technical help, translated materials, local nursing, or hybrid options, then monitor recruitment and retention across participant groups.
9. Pressure to Improve Trial Efficiency and Costs
Travel, site coordination, missed appointments, and manual data handling can increase costs and delay trials. Remote procedures may reduce some burdens and maintain contact between visits.
Savings are not automatic: technology, devices, home nursing, delivery, cybersecurity, and vendor coordination also cost money. Sponsors should compare total costs and timelines, tracking recruitment speed, retention, protocol deviations, data-query rates, participant burden, and cost per completed participant.
10. AI and Data-Driven Trial Management
Analytics and AI can help identify enrollment patterns, flag retention risks, prioritize follow-up, and detect operational bottlenecks across distributed trials. Timely signals may allow teams to intervene before small issues become delays.
Value depends on data quality, transparency, validation, and human accountability. Sponsors should define which decisions analytics support, who reviews recommendations, and how actions are documented. AI can improve coordination but cannot replace clinical judgment, participant communication, or sound trial design. Governance should include monitoring for model drift and checking whether performance differs across relevant participant groups.
Strategic Implications for Clinical Development Leaders
Start with the protocol and participant journey, then classify activities as remote, locally supported, or site-based. A hybrid design may outperform an attempt to eliminate every visit.
Plan vendor responsibilities, participant support, escalation, data flows, cybersecurity, and quality oversight before launch. Measure recruitment, retention, participant experience, data completeness, compliance, safety response, timelines, and total cost to determine whether decentralization creates value rather than shifting work to participants or vendors.
What Will Define the Future?
Interoperability, validated remote endpoints, dependable home services, and accessible tools may broaden the studies that can use decentralized methods. Therapeutic area, product characteristics, participant needs, and regulatory expectations will continue to shape the balance between remote and in-person procedures.
Key Takeaways
- Site-less trials relocate suitable activities; they do not eliminate all in-person care.
- Telehealth and connected devices support remote follow-up and measurement.
- Home delivery requires product controls and participant education.
- eConsent must protect informed choice, accessibility, and documentation.
- Platforms need interoperability, privacy, and vendor oversight.
- Digital biomarkers require validation and a clear clinical purpose.
- Inclusion requires addressing digital access barriers.
- Efficiency should be measured through total cost, data quality, retention, and safety.
- AI supports operations only when transparent and subject to human oversight.
Conclusion
Site-less clinical trials extend decentralized research through telehealth, remote monitoring, digital documentation, home delivery, and connected data systems. The decision is how to match trial design to the science and participants. Carefully selected remote procedures, strong operational controls, and measurable outcomes will determine where site-less approaches deliver lasting value.
Clinical Trials are undergoing a major transformation as pharmaceutical companies, biotechnology firms, and research organizations explore ways to conduct studies beyond traditional research facilities. Site-less clinical trials, often associated with decentralized clinical trials, use digital technologies, remote healthcare services, and home-based procedures to reduce the need for participants to visit a physical study site for every activity.
Traditional research models can require frequent hospital visits, long-distance travel, time away from work, and complicated scheduling. These demands may discourage eligible participants from enrolling or make it difficult for them to remain involved throughout a study. Site-less approaches aim to reduce these burdens while maintaining participant safety, reliable data collection, and appropriate clinical oversight.
Advances in telehealth, wearable devices, electronic consent, home nursing, and direct-to-patient services are making remote research more practical. However, not every study can be conducted entirely remotely. The appropriate model depends on the investigational treatment, study population, safety requirements, and procedures involved.
What Are Site-less Clinical Trials?
Site-less Clinical Trials are studies designed to conduct some or most research activities outside conventional research facilities. Participants may complete questionnaires online, attend virtual consultations, use connected devices, receive study materials at home, or arrange laboratory tests and nursing visits at convenient locations.
Top 10 Drivers Behind Site-less Clinical Trials
1. Greater Patient Convenience
One of the biggest drivers is the ability to reduce the time and effort required to participate in research. Traditional study visits can involve travel, parking expenses, waiting periods, and time away from employment or family responsibilities.
Remote consultations and home-based assessments can make participation more manageable. For people living with chronic conditions or mobility limitations, fewer required trips may be particularly valuable.
Improving convenience can support recruitment and retention, although the actual impact depends on the study design and participants’ circumstances.
2. Wider Access to Participants
Traditional research centers are often concentrated in major cities or specialist hospitals. People living in rural communities and underserved regions may have limited access to nearby studies.
Site-less Clinical Trials can expand geographic reach by allowing selected activities to take place in participants’ homes or local healthcare settings. This may help researchers engage people who would otherwise face substantial travel barriers.
Broader access does not automatically guarantee representative enrollment. Sponsors must still address internet access, language, digital literacy, eligibility criteria, and other barriers that affect participation.
3. Growth of Telehealth
Telehealth enables healthcare professionals and study teams to communicate with participants through secure video consultations, telephone calls, and other remote communication tools.
These services can support follow-up visits, symptom discussions, medication reviews, and selected safety assessments. They may also help participants obtain timely guidance without traveling to a research center.
Telehealth cannot replace every physical examination or clinical procedure. Research teams must determine which assessments can be completed remotely without compromising participant safety or data quality.
4. Advances in Wearable Devices
Wearable devices and connected medical technologies can collect information such as heart rate, activity levels, sleep patterns, and other relevant measurements, depending on the device.
In Clinical Trials, these tools may help researchers monitor changes over time rather than relying exclusively on measurements collected during scheduled visits.
Continuous or frequent data collection can provide valuable insights into daily functioning and treatment effects. However, devices must be appropriate for the intended purpose, and teams need procedures for handling missing data, device failures, participant adherence, and data quality.
5. Faster and More Flexible Recruitment
Recruiting participants can be a major challenge for pharmaceutical research. Traditional recruitment may depend on people living close enough to a research center and being able to attend repeated visits.
Remote recruitment tools, digital outreach, and virtual screening can help research teams connect with potential participants across wider geographic areas.
A larger recruitment pool may improve the chances of identifying eligible candidates. Nevertheless, online screening must protect personal information, verify eligibility appropriately, and avoid misleading participants about the study or its potential benefits.
